Clinical trials: Elderly Adults
Tuberculosis
A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine…
- Trial name
- NCT06732583
- Testing
- Tuberculosis (TB) vaccine (Ad5-105K), Ad5-105K
- Where
- Indonesia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19 Vaccine) and determine the recommended dose in Japanese healthy adults and elderly participants.
- Trial name
- NCT04821674
- Testing
- DS-5670a
- Where
- Japan
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Influenza, Human
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04576702
- Testing
- Investigational aIIV4c, IIV4c, aIIV4
- Where
- 21 sites in United States
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults
This Phase 2, randomized, observer-blind, antigen and adjuvant dose-ranging Clinical study is evaluating different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine.
- Trial name
- NCT04782323
- Testing
- aQII-1, aQII-3 Investigational, aQII-6 Investigational
- Where
- 30 sites in Australia, New Zealand and 2 more
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Seqirus
Age Related Cognitive Decline
Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training
The proposed SBIR Phase I study tests the feasibility of PATH neurotraining for improving cognitive skills in older adults and, potentially, forestalling or protecting against cognitive decline and dementia.
- Trial name
- NCT03456986
- Testing
- PATH neurotraining, Orientation Discrimination
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Perception Dynamics Institute
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Clostridium Difficile
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.
- Trial name
- NCT02052726
- Testing
- C. difficile vaccine with adjuvant
- Where
- 10 sites in United States, Canada
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
This study is designed to test the safety and immunogenicity of Fluviral® (2010 - 2011 Season) in adults aged 18 to 60 years and over 60 years.
- Trial name
- NCT01153685
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
MHNA-001 for Young Adults With IBS
The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ IBS together with care as usual in approximately 100 young adults with Irritable Bowel Syndrome.
- Trial name
- NCT05333926
- Testing
- MHNA-001
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Mahana Therapeutics
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00319098
- Testing
- Adjuvanted pandemic influenza candidate vaccine, Fluarix
- Where
- 40 sites in Estonia, France and 5 more
- Volunteers
- 5,075 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety and preliminary immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60…
- Trial name
- NCT05354063
- Testing
- 20 μg dose of SYS6006, 30 μg dose of SYS6006
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Covid19
Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults
This study is a randomized, double-blinded clinical Trial, to evaluate the non-inferiority of the commercial scale Inactivated SARS-CoV-2 vaccine against that of the pilot scale among adults aged 26-45 years, and the…
- Trial name
- NCT04617483
- Testing
- Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14, Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
- Where
- China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Healthy
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects
The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of intranasally administered esketamine in elderly Japanese subjects and healthy younger adult Japanese subjects.
- Trial name
- NCT02857777
- Testing
- Esketamine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Infection, Meningococcal
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine
- Trial name
- NCT04714229
- Testing
- Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine, Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Influenza
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free…
- Trial name
- NCT00579345
- Testing
- Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a
- Where
- 5 sites in Poland
- Volunteers
- 1,522 people, healthy volunteers welcome
- Sponsor
- Novartis
Healthy Volunteers
A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults
The purpose of this study is to describe the side effects and immune response of a candidate vaccine that might protect against Zika.
- Trial name
- NCT05469802
- Testing
- Purified Inactivated Zika Virus Vaccine (PIZV)
- Where
- 5 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT01146015
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals